TENK: TenX Keane Acquisition Stock

by  •  • Comments Off on TENK: TenX Keane Acquisition Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) n/a
Book Value / Share n/a
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share n/a
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) n/a
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets n/a
Assets n/a
Liabilities n/a
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue n/a
Operating Income n/a
Net Income n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations n/a
Cash from Investing n/a
Cash from Financing n/a

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
09-05 13G/A Wolverine Asset Management Llc 0.00 -100.00
03-07 13G/A Karpus Management, Inc. 0.00 -100.00
02-13 13G Mizuho Financial Group Inc 5.84
02-05 13G/A Space Summit Capital LLC 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE)
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2023-11-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE)

(click for more detail)

Similar Companies
ACAB – Atlantic Coastal Acquisition Corp. II ACET – Adicet Bio, Inc.
ACIU – AC Immune SA ACRV – Acrivon Therapeutics, Inc.
ADMA – ADMA Biologics, Inc.


Financial data and stock pages provided by
Fintel.io